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Abstract
Background: Activin receptor-like kinase 1 (ALK1) is a Transforming Growth Factor-b (TGF-b) receptor type I,
mainly expressed in endothelial cells that plays a pivotal role in vascular remodelling and angiogenesis. Mutations
in the ALK1 gene (ACVRL1) give rise to Hereditary Haemorrhagic Telangiectasia, a dominant autosomal vascular
dysplasia caused by a haploinsufficiency mechanism. In spite of its patho-physiological relevance, little is known
about the transcriptional regulation of ACVRL1. Here, we have studied the different origins of ACVRL1 transcription,
we have analyzed in silico its 5′-proximal promoter sequence and we have characterized the role of Sp1 in the
transcriptional regulation of ACVRL1.
Results: We have performed a 5′Rapid Amplification of cDNA Ends (5′RACE) of ACVRL1 transcripts, finding two new
transcriptional origins, upstream of the one previously described, that give rise to a new exon undiscovered to
date. The 5′-proximal promoter region of ACVRL1 (-1,035/+210) was analyzed in silico, finding that it lacks TATA/
CAAT boxes, but contains a remarkably high number of GC-rich Sp1 consensus sites. In cells lacking Sp1, ACVRL1
promoter reporters did not present any significant transcriptional activity, whereas increasing concentrations of Sp1
triggered a dose-dependent stimulation of its transcription. Moreover, silencing Sp1 in HEK293T cells resulted in a
marked decrease of ACVRL1 transcriptional activity. Chromatin immunoprecipitation assays demonstrated multiple
Sp1 binding sites along the proximal promoter region of ACVRL1 in endothelial cells. Furthermore, demethylation
of CpG islands, led to an increase in ACVRL1 transcription, whereas in vitro hypermethylation resulted in the
abolishment of Sp1-dependent transcriptional activation of ACVRL1.
Conclusions: Our results describe two new transcriptional start sites in ACVRL1 gene, and indicate that Sp1 is a key
regulator of ACVRL1 transcription, providing new insights into the molecular mechanisms that contribute to the
expression of ACVRL1 gene. Moreover, our data show that the methylation status of CpG islands markedly
modulates the Sp1 regulation of ACVRL1 gene transcriptional activity.
Background
ALK1 (Activin receptor-Like Kinase 1) is a transmem-
brane type I receptor of the Transforming Growth Fac-
tor-b (TGF-b) superfamily of ligands, mainly found in
endothelial cells. Its expression has been reported not
only in highly vascularized tissues including lung, pla-
centa, and heart [1,2], but also at specific sites of
epithelial-mesenchymal interactions [3], and in other
cell types such as monocytes [4], microglia [5], skin
fibroblasts [6], stellate hepatic cells [7], chondrocytes
[8], neural crest stem cells [9] and more recently myo-
blasts [10]. Nonetheless, most studies to date suggest
that its major roles are related to the endothelial specific
expression pattern. ALK1 is involved in angiogenesis
[11,12], and there is growing evidence indicating that it
plays a key function in the arterial/venous differentiation
during embryonic vascular development [13,14]. It has
been reported that ALK1 interacts with three ligands:
with TGF-b1 and TGF-b3, in complex with the receptor
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Protein 9 (BMP9), in complex with the Activin Receptor
type IIA (ActRIIA) or the BMP receptor type II
(BMPRII) [16]. In the endothelium, circulating TGF-b
signals from the lumen of the vascular vessel to the
cytoplasm of the endothelial cell by interacting with its
specific receptor complex. This complex consists of
three different dimeric proteins: receptor type II (TbR-
II), receptor type I (TbR-I) and an ancillary co-receptor
(TbR-III: Betaglycan or Endoglin) [17]. ALK5 is the pre-
dominant TbR-I in the majority of the cell types, but in
endothelial cells ALK1 shares the TbR-I function with
ALK5 in vitro. The significance of this apparent redun-
dancy is explained because ALK1 and ALK5 signal in
opposite directions, balancing the TGF-b signalling
pathway in this cell type [11]. ALK5 is able to arrest the
cell growth, leading to a differentiated state in the
maturation phase of angiogenesis, with formation of
new extracellular matrix around the new vessel formed.
ALK1 appears to play opposite physiological functions,
since it is responsible for the events occurring during
the activation phase of angiogenesis, including metallo-
protease activation, proliferation of endothelial cells, and
inhibition of differentiation [18]. Thus, these comple-
mentary effects are mediated through different target
genes of the two signalling pathways. ALK5 signals
through Smad2/3 to regulate PAI-1 (Plasminogen Acti-
vator Inhibitor-1), Collagen I,o rNOS-3/eNOS (Endothe-
lial Nitric Oxide Synthase), whereas ALK1 signals
through Smad1/5/8 to induce genes involved in prolif-
eration such as Id1 (Inhibitor of differentiation 1), Id2
(Inhibitor of differentiation 2), Smad6, Smad7, ENG
(Endoglin) or BMPRII [19]. In addition, it has been
shown that BMP9 is a quiescence factor for the micro-
vasculature [20].
T h eg e n ee n c o d i n gA L K 1( ACVRL1, Activin-A recep-
tor type II-like kinase 1) spans 15,943 bp within the
large arm of chromosome 12 (12q11-q14), coded on the
positive strand (GeneID: 94). ACVRL1 cDNA was
described first in 1993 simultaneously by two different
groups showing a characteristic transcriptional start site
(TSS), where the first exon is transcribed but not trans-
lated. To date, two different variants of mRNA tran-
scripts have been described: variant 1 [GenBank:
NM_000020.2] [21] and variant 2 [GenBank:
NM_001077401.1] [22], both encoding the same ALK1
protein of 503 amino acids.
Mutations in ACVRL1 give rise to an autosomal vas-
cular dysplasia called Hereditary Haemorrhagic Telan-
giectasia type 2 (HHT2) [1], while HHT type 1 is caused
by mutations in ENG, the gene coding for the TGF-b
co-receptor Endoglin [23]. HHT1 and HHT2 are geneti-
cally dominant and mutant homozygosis is lethal, as
confirmed in knock out mice for ENG and ACVRL1
[24-26]. Current estimates suggest that one in 5,000-
8,000 people are affected by HHT [27]. Patients are
clinically diagnosed according to the Curaçao criteria
[28], including nose bleeds, mucocutaneous telangiec-
tases, internal arteriovenous malformations and familial
inheritance. Around 90% of HHT patients have been
genetically diagnosed as HHT1 or HHT2, and multiple
mutations along exonic regions of ACVRL1 and ENG
have been described [29]. Because approximately 10% of
HHT patients clinically diagnosed have unidentified
mutations, the study of intronic sequences, splice sites
and promoter regions of both genes is of critical impor-
tance. Moreover, haploinsufficiency is currently accepted
as the basis for the pathogenicity of HHT [29] and
therefore the understanding of the transcriptional
mechanisms and the assessment of ways to increase the
transcription rate may be crucial to identify strategies to
counteract haploinsufficiency. While several reports
have already described the organization and control of
ENG promoter [30-33], very little has been done in rela-
tion to the ACVRL1 promoter. In this work, we have
analyzed the 5′-proximal ACVRL1 promoter region,
characterized new transcriptional initiation points, and
analyzed the transcriptional mechanisms that regulate
its expression.
Results
Identification of novel TSSs for human ACVRL1 gene
revealed by 5′RACE
In order to characterize the origins of ACVRL1 tran-
scription in endothelial cells, a 5′RACE of total RNA
obtained from HUVECs was performed. After nested
PCR, the amplified bands were cloned and sequenced
(Figure 1A and 1B). The three major products amplified
correspond to three different 5′flanking regions. More
than 50% of the clones corresponded to the mRNA1 of
ACVRL1 previously described [21], whereas two new
TSSs (mRNA3 and mRNA4) were also identified in sev-
eral clones from independent experiments (Figure 1B).
Interestingly, both alternative mRNAs begin the tran-
scription upstream the TSS (+ 1), in the positions -510
and -470, respectively. Accordingly, the exons have been
renumbered in this work in such a way that the new
exon 1 is upstream of the previously described TSS
(+ 1). The numbering of the TSS (+ 1) has been main-
tained because it appears to be the predominant TSS.
Thus, the previously considered exon 1 turns into exon
2, being named 2A, in the case of NM_000020.2 and 2B
in the case of NM_001077401. Likewise, the newly dis-
covered upstream exon now becomes exon 1, named 1A
in the mRNA3, or 1B, in the variant mRNA4.
Figure 1C shows the scheme of all the ACVRL1 tran-
script variants found in this work (mRNA1, 3 and 4)
and in previous reports (mRNA1 and 2). The variant
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Page 2 of 22Figure 1 5′ Rapid Amplification of cDNA Ends (5′RACE) of ACVRL1 transcripts from HUVECs. Electrophoretic analysis of nested PCR
amplification products. Lanes: 1 and 2 (without template; outer and inner nested PCRs), 3 and 4 (RNA without CIP/TAP treatment; outer and
inner), 5 and 6 (CIP/TAP treated RNA; outer and inner). More than 10 different experiments were performed and three representative gels are
shown. (B) Nucleotide sequence of the products. Primers used are underlined. Grey boxes indicate the junctions between different exons. The
predominant transcript found in HUVECs corresponds to the mRNA1 previously described in placenta. Two novel variants described in this work
have been named mRNA3 [GenBank:HM161905] and mRNA4 [GenBank:HM161906]. Numbers are given according to the genomic sequence from
+ 1 TSS. Fragments starting from -510 of mRNA3 and from -470 of mRNA4 are the newly observed transcribed regions. The sequences of these
three isoforms are identical downstream from + 79. (C) Schematic representation of the 5′ flanking region of ACVRL1 transcripts. The previously
described mRNA1 [GenBank:NM 000020.2] and mRNA2 [GenBank:NM 001077401.1], and mRNA3 and mRNA4 found in this work are shown. All
ACVRL1 encoded proteins found to date have the same 503 amino acid sequence. mRNA1 has been found with the same characteristics as
previously described. Taking into account the new sequence, ACVRL1 rearranges from 10 to 11 exons; starting the new exon 1 at -510 (variant
1A) or -470 (variant 1B). Also, previously described exon 1 is renamed as exon 2 (variants 2A and 2B). Red arrows represent the two newly
described TSSs. Blue arrows represent the two TSSs previously known.
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of 278 bp (exon 2A) and then upon splicing of the long-
e s ti n t r o n( ~5k b )o fACVRL1, it continues with an
exonic sequence containing the ATG start codon (exon
3). The mRNA2 has no exon 2A, and its exon 3 is
longer in its 5′region, containing an additional 141 bp
fragment. The starting ATG is located at the beginning
of exon 3 (+ 5,058/+5,060), coinciding with mRNA1,
therefore, both transcripts give rise to the same 503
amino acid protein.
The fragments obtained in the present work corre-
spond to isoforms mRNA3 and mRNA4. The corre-
sponding cDNA sequences have been deposited in
GenBank database with accession numbers HM161905
and HM161906, respectively. Both of them reveal a
cryptic exon placed upstream the + 1, resulting in two,
instead of one, transcribed but not translated exons.
This event gives rise to a rearrangement from 10 to 11
exons in the composition of the coding region of
ACVRL1.
The human ACVRL1 promoter lacks TATA/CAAT boxes
and has multiple Sp1 motifs
Human ACVRL1 gene resides on chromosome 12q11-
q14 [34]. Thus, a 1,244 bp fragment comprising from
position -50,586,434 to position -50,587,679 of the
contig [GenBank:NC_000012.10, Reference assembly]
was amplified by PCR from human genomic DNA
(Figure 2). This fragment corresponds to positions
from -1,035 bp to + 210 bp relative to the (+ 1) TSS.
Interestingly, this 5′-proximal regulatory region of
ACVRL1 lacks TATA and CAAT boxes. A predictive
in silico analysis of ACVRL1 promoter using the Geno-
matix MatInspector software tool revealed a very high
number of GC-rich regions and multiple putative Sp1
binding consensus sites (Table 1). Fourteen different
possible sites for Sp1 interaction were found, located
in both strands: Forward strand (Sites -810/-796,
-734/-720, -728/-714, -524/-510, -435/-421, -88/-74,
-70/-56 and + 15/+30); and reverse strand (Sites -919/-
905, -411/-397, -401/-387, -309/-295, -184/-170 and +
124/+139). All of these sites have a very high similarity
with the theoretical matrix (score > 0.85). Three AP1
and four AP4 sites were found dispersed along the
sequence. In addition, the 5′-flanking sequence of
ACVRL1 gene contains several putative regulatory ele-
ments also present in other endothelial genes (see Fig-
ure 2 and Table 1). These consensus elements include
eight motifs for the Ets (E26-Transformation-Specific)
family of transcription factors, 23 sequences sensitive
for KLF (Krüppel-Like Factor) recognition, seven NFB
(Nuclear Factor kappa-light-chain-enhancer of acti-
vated B cells) motifs, five E2F (Elongation Factor 2)
consensus sequences, one Smad binding element (SBE)
and seven sites for RXR (Retinoid X Receptor) dimers.
Moreover, three HIF (Hypoxia Inducible Factor) con-
sensus sequences were found distributed along the
ACVRL1 promoter sequence.
The ACVRL1 promoter region is highly conserved among
different species
The ACVRL1 proximal promoter sequence has several
features that suggest a high level of regulation. One of
these features is the possibility to begin the transcription
in different points. To evaluate the importance of each
putative regulatory site, the ACVRL1 promoter of sev-
eral mammalian species were compared using the Clus-
talW2 algorithm. The species analyzed included mouse,
rat, cow, orangutan, rhesus monkey, horse, chimpanzee
and dog. For the alignments, we selected the same
region than the one we were studying in humans (from
-1,035 bp to + 210 bp of the TSS). Figure 3 shows the
comparative alignment of the ACVRL1 human sequence
surrounding the different TSSs with the same regions in
other animal species. Panel A shows a scheme of the
regions aligned in panel B. The previously described
TSS (identified by the + 1) has a highly conserved
sequence among primates (AGGAAACGG), suggesting
an important functional role. Moreover, the two newly
described TSSs are conserved only in this group of spe-
cies (-510 bp AAAACGC in exon 1A and -470 bp
ATTGCT in exon 1B). Of note, both sequences at the
beginning of exons 1A and 1B are less conserved than
the region surrounding TSS (+ 1).
Another interesting feature about the putative
ACVRL1 promoter is the high number of Sp1 consensus
sites along the sequence, and near to the TSSs. These
sites are important as possible key regulators for
ACVRL1 transcription, so we compared these motifs
among different species. The scheme of Sp1 sites pre-
sent in the sequence is shown in Figure 4A. The align-
ments of these fragments and the same regions from
other animal species are included in Figure 4B. Of note,
these sites appear highly conserved, especially between
humans and other primates, which is a characteristic of
promoters under Sp1 regulation and lacking TATA/
CAAT boxes.
Basal activity of ACVRL1 promoter suggests the presence
of possible positive and negative regulatory regions
To assess the transcriptional activity of the ACVRL1 pro-
moter fragment, it was cloned into a luciferase reporter
vector. A schematic representation of the ACVRL1 pro-
moter fragment cloned into pGL2-luc, with the locations
of the different TSS and the ATG translation start codon,
i ss h o w ni nF i g u r e5 A .S e r i a l5 ′-deleted constructs from
-1,035 bp to -284 bp of the ACVRL1 proximal promoter
were generated (Figure 5B,l e f t )a n dt h e i rb a s a l
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Page 4 of 22transcription activity assessed in HMEC-1. In this
endothelial cell line, the shortest construct maintains the
majority of the transcriptional activity, whereas the -422/
+59 construct displays one third of the activity compared
with the whole sequence (Figure 5B, right). In order to
unravel if ACVRL1 could be transcriptionally regulated
by its own ligands, the effect of TGF-b1o rB M P 9w a s
assessed. HMEC-1 cells were transfected with different
pALK1 reporter constructs and treated with either TGF-
b1o rB M P 9u s i n gt h et i m ea n dd o s ep r e v i o u s l y
established in endothelial cells [35]. None of these treat-
ments had a significant effect on the transcriptional activ-
ity of the reporter constructs, except for the construct
-422/+59, whose basal activity seems to be slightly upre-
gulated in the presence of BMP9 (Figure 5C).
Sp1 is critical for the ACVRL1 basal transcription
Since 14 putative target sequences for Sp1 were pre-
dicted in the ACVRL1 promoter, their contribution to
the basal activity was assessed in Schneider Drosophila
Figure 2 Nucleotide sequence of the 5′-flanking region of the ACVRL1 gene and in silico analysis of the putative transcription factor
binding sites. Red arrows show the newly described TSSs (-510 and -470). The blue arrow indicates the already described TSS (+ 1). The
sequence lacks TATA and CAAT boxes. Putative transcription factor binding motifs for AP1 (Activator protein 1), AP4 (Activator protein 4), CEBP
(CCAAT/Enhancer Binding protein), E2F (Elongation Factor 2), EKLF/KLF1 (Krüppel-Like Factor 1), ETS (E26-Transformation Specific transcription
factor), GKLF/KLF4 (Krüppel-Like Factor 4), HIF (Hypoxia Inducible Factor), NFB (Nuclear Factor of kappa light polypeptide gene enhancer in B-
cells), RXR (Retinoid X Receptor), Smad (Sma and Mad-related factor), Sp1 and ZF9/KLF6 (Krüppel-Like Factor 6) are indicated by boxes. The core
consensus sequences for each factor are in bold. A large number of Sp1 consensus binding sites are present in the sequence. Data were
generated using the Genomatix MatInspector software tool.
Garrido-Martin et al. BMC Molecular Biology 2010, 11:51
http://www.biomedcentral.com/1471-2199/11/51
Page 5 of 22embryonic S2 cells. These cells are undifferentiated and
do not express endogenous Sp1 or any other related
member of its family. As shown in Figure 6A, left, the
proximal promoter of ACVRL1 shows background levels
of basal activity in the absence of Sp1. By contrast, ecto-
pic expression of Sp1 shows a dramatic effect on pALK1
activity. Even with very low amounts of the transfected
Sp1 expression vector, the basal transcription of pALK1
is increased ~ 100 fold following a dose-response curve.
There is a saturating effect around 25 ng Sp1 where the
promoter is stimulated ~500 fold. The same experiment
performed in HEK293T cells resulted in the stimulation
of the basal activity up to 3-fold (Figure 6A, right). This
moderate increase, as compared to S2 cells (~500 fold),
Table 1 Main putative transcription factor binding sites found in the ACVRL1 promoter region
Family Start pos. End pos. Str. Matrix sim. Core sim. Family Start pos. End pos. Str. Matrix sim. Core sim.
AP1 -875 -855 - 0.823 1.0 HIF -808 -792 + 0.85 0.9
-873 -853 + 0.899 0.813 -286 -274 + 0.885 1.0
-871 -851 - 0.994 1.0 -236 -219 - 0.843 0.75
AP4 -881 -865 - 0.923 1.0 NFKB -851 -839 + 0.901 1.0
-820 -804 - 0.87 0.882 -786 -774 + 0.852 1.0
-506 -490 - 0.961 1.0 -784 -772 - 0.919 1.0
+179 +195 - 0.855 1.0 -534 -522 + 0.985 1.0
CEBP -432 -418 + 0.945 0.971 -533 -521 - 0.947 1.0
EKLF/KLF1 -918 -902 - 0.924 1.0 -220 -208 + 0.84 1.0
-886 -870 - 0.911 1.0 -158 -146 + 0.838 1.0
-808 -792 + 0.975 1.0 RXR -979 -955 + 0.954 1.0
-737 -721 + 0.932 1.0 -871 -847 + 0.758 0.771
-731 -715 + 0.917 1.0 -864 -840 + 0.818 0.824
-433 -417 + 0.977 1.0 -535 -511 + 0.847 0.952
-410 -394 - 0.933 1.0 -441 -417 + 0.763 0.812
-405 -389 - 0.95 1.0 -314 -290 - 0.819 0.81
-313 -297 - 0.974 1.0 -230 -206 - 0.791 0.905
-241 -225 - 0.916 1.0 SMAD -270 -262 + 0.969 1.0
-107 -91 + 0.923 1.0 SP1 -919 -905 - 0.901 0.807
-73 -57 + 0.916 1.0 -810 -796 + 0.885 0.872
-68 -52 + 0.971 1.0 -734 -720 + 0.997 1.0
+125 +141 - 0.947 1.0 -728 -714 + 0.879 1.0
ETS -939 -919 + 0.961 1.0 -524 -510 + 0.913 1.0
-797 -777 + 0.922 1.0 -435 -421 + 0.881 0.872
-791 -771 + 0.965 1.0 -411 -397 - 0.89 0.807
-758 -738 - 0.943 1.0 -401 -387 - 0.895 0.872
-699 -679 + 0.972 1.0 -309 -295 - 0.891 0.872
-388 -368 - 0.945 1.0 -184 -170 - 0.98 1.0
-373 -353 - 0.914 1.0 -88 -74 + 0.885 1.0
+36 +56 + 0.927 1.0 -70 -56 + 0.892 0.872
E2F -493 -477 + 0.849 1.0 +15 +30 + 0.987 1.0
-143 -127 - 0.861 0.81 +124 +139 - 0.93 0.877
+98 +114 - 0.971 1.0 ZF9/KLF6 -815 -793 - 0.891 0.923
+99 +115 + 0.964 1.0 -739 -717 - 0.899 1.0
+150 +166 - 0.875 1.0 -148 -126 - 0.881 1.0
GKLF/KLF4 -981 -969 + 1.000 0.862 -109 -87 - 0.897 0.821
-600 -588 + 1.000 0.883 -86 -64 - 0.879 1.0
-3 +9 + 0.770 0.868 +150 +172 + 0.936 1.0
Note: Start/End pos, starting/ending position of the consensus site in the sequence; Str, Strand-sense; Matrix sim, Matrix (groups of functionally similar
transcription factors) similarity factor (0-1); Core sim, Core consensus sequence (4 highest conserved positions) similarity factor (0-1); AP1, Activator Protein 1;
AP4, Activator Protein 4; CEBP, CCAAT/Enhancer Binding Protein; EKLF, Erythroid Krüppel-Like Factor; ETS, E26-Transformation-Specific transcription factor; E2F,
Elongation Factor 2; GKLF, Gut-related Krüppel-Like Factor; HIF, Hypoxia Inducible Factor; NF?B, Nuclear Factor of kappa light polypeptide gene enhancer in B-
cells; RXR, Retinoid X Receptor; SMAD, Sma and Mad-related; SP1, Specificity Protein 1; ZF9, Krüppel-like Zinc Finger protein 9.
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Page 6 of 22Figure 3 Sequence alignment of the human ACVRL1 TSSs across different mammalian species. (A) Scheme of the human sequences used
for the alignment. The blue arrow indicates the previously described TSS (+ 1). The red arrows indicate the new TSSs identified in Figure 1. (B)
Sequences from chimpanzee, orangutan, rhesus monkey, cow, dog, horse, mouse and rat were compared with the human -1,035/+210
sequence. Sequences were obtained from NCBI-GenBank and EMBL databases (see Methods). Asterisks indicate the totally conserved residues
across species. Alignments of the putative regulatory sites are shown with a colored background based on the identity between species. The
degree of homology is: black > dark grey > light grey. Score means percentage of identity with the human sequence. Brackets indicate exonic
sequences.
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Page 7 of 22Figure 4 Sp1 consensus binding sites located along the human ACVRL1 promoter and alignment with other mammalian species. (A)
Schematic representation of the 14 Sp1 consensus sites found in silico along the -1,035/+210 fragment of ACVRL1 promoter sequence. Red
arrows show the newly described TSSs. The blue arrow indicates the already described TSS (+ 1). (B) Alignment with other mammalian species
(source of sequences as in Figure 3). Numbers are referred to the human sequence and range from -1,035 to + 210 bp. Asterisks indicate the
totally conserved residues across species. Alignments of the putative regulatory sites are shown in grey background. All the human nucleotides
selected for the alignment (grey background) have a Ci-value > 60. Ci = Consensus index value. It represents the degree of conservation of each
position within the matrix. Putative core sequences for the binding of Sp1 are underlined. The core sequence (usually 4 residues) of a matrix is
defined as the most conserved with the theoretical consensus. Additional information about each site can be found in Table 1.
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Page 8 of 22is likely due to the endogenous expression of Sp1 in
HEK293T cells. Thus, small amounts of Sp1 expression
are sufficient to saturate all the Sp1 sites in the ACVRL1
promoter, leading to the maximum transcriptional activ-
ity that the promoter can achieve.
The next step was to dissect the Sp1 transcription
induction in the different promoter constructs. S2 cells
were co-transfected with Sp1 and with the different 5′-
deleted constructs of the reporter pALK1 (Figure 6B).
All constructs showed low basal transcriptional activ-
ities, which have been referred to value 1 and the stimu-
lation is expressed as fold induction. When as little as
25 ng of the Sp1 expression vector was transfected, the
activity levels of each construct were remarkably stimu-
lated (between 26- to 158-fold induction values). It is
worth mentioning that the maximum activity reached by
the -422/+59 construct did not parallel its relatively low
activity in endothelial cells, which have basal Sp1 levels
(Figure 5B). This discrepancy is probably explained by
the different background of transcription factors present
in Drosophila embryonic versus human HMEC-1 cells.
To further assess the relevance of Sp1 in ACVRL1
transcription, Sp1 expression was abolished in mamma-
lian Sp1-expressing cells. Thus, HEK293T cells trans-
fected with siRNA targeted to Sp1 led to a marked
decrease (more than 50%) of the ACVRL1
Figure 5 Transcriptional activity of the human ACVRL1 promoter. (A) Schematic representation of the ACVRL1 promoter fragment cloned
into the promoterless pGL2-luc reporter vector with the three TSS. (B) Left, 5′-deleted construct series of the whole sequence obtained by PCR
and cloned into pGL2-luc. The size of each construct compared with the size of the whole promoter construct is shown in the scheme. Right,
transient transfection of ACVRL1 promoter 5′-deleted constructs in the human endothelial cell line HMEC-1. Transfection efficiency was corrected
by relating luciferase activity to b-galactosidase activity. Results are expressed as a percentage of activity respect to the activity of the full length
construct (-1,035/+210; 100%) (*p < 0.05, **p < 0.01 versus -1,035/+210 pALK1 construct). (C) Effect of ALK1 ligands TGF-b1 and BMP9 on ACVRL1
promoter activity. HMEC-1 cells were transiently transfected with ACVRL1 5′-deleted mutants, and pretreated with 1 ng/ml TGF-b1 for 3 hours or
0.5 ng/ml BMP9 for 15 hours. Results are shown in fold induction values respect to basal activity. No significant effect on ACVRL1 promoter
activity was observed, except a little increase with BMP9 on the -422/+59 construct (*p < 0.05; **p < 0.01; ns = not significant).
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Page 9 of 22Figure 6 Effect of Sp1 expression on ACVRL1 promoter activity. (A) Dose-response effect of Sp1 on the transcriptional activity of ACVRL1
promoter in Schneider S2 and HEK293T cells. S2 (Sp1-less) and HEK293T cells were cotransfected with the pGL2 empty vector or the ACVRL1
promoter construct -1,035/+210 and with increasing amounts of the Sp1 expression vector (pPac-Sp1 and pCIneo-Sp1, respectively). Luciferase
activity was corrected with b-galactosidase activity and expressed as fold induction of the transcriptional activity of pALK1 in the absence of
exogenous Sp1. (B) Left, scheme showing the distribution of the different Sp1 consensus binding sites along the ACVRL1 promoter (black ovals)
in the different constructs. Right, transient transfection of Schneider S2 cells with 25 ng of pPac-Sp1 and the indicated ACVRL1 promoter
constructs. Fold-induction values respect to basal activity are indicated on top of each bar. (C) Effect of Sp1-knock down on ACVRL1
transcriptional activity. HEK293T cells were transfected with Sp1 siRNA. Left, Sp1 mRNA and protein levels were measured by semiquantitative RT-
PCR and western blot after 48 hr. Right, 24 hr after the siRNA Sp1 transfection, the different ACVRL1 promoter constructs were transfected. The
transcriptional activity of all the fragments was measured and normalized by the b-galactosidase activity. Basal pALK1 activity (100%) and the
reduction after Sp1 silencing (grey bars) are shown. In every case, Sp1 suppression resulted at least in a decrease of 50% in ACVRL1
transcriptional activity (***p < 0.005).
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Page 10 of 22transcriptional activity in all the constructs (Figure 6C).
These data confirm that Sp1 is essential for the tran-
scriptional activity of the ACVRL1 promoter.
Chromatin immunoprecipitation of endogenous Sp1
bound to ACVRL1 promoter in HUVECs
Because Sp1 is clearly able to stimulate the basal tran-
scription of ACVRL1 in vitro, it was of interest to assess
whether the physical binding of Sp1 to the ACVRL1
promoter occurs within the endothelial cells. For this
purpose, a chromatin immunoprecipitation (ChIP) of
endogenous Sp1 was performed in HUVECs. Four dif-
ferent regions were screened, spanning the whole
-1,035/+210 bp sequence of ACVRL1 promoter (Figure
7A). PCR amplification yielded positive bands along the
four fragments, suggesting that Sp1 is normally bound
to all these fragments of the ACVRL1 promoter and,
consequently, most of the putative theoretical binding
sites are functionally active (Figure 7B). Densitometric
analysis of the PCR enriched fragments revealed that all
of them showed a clear Sp1 binding above background,
yielding the strongest signal the fragment -510/-260
(Figure 7D). As a negative control, the erythropoietin
(EPO) promoter, containing a Sp1 motif that recruits
Sp1 only under hypoxic conditions [36], was used. In
fact, the ChIP experiment demonstrated that Sp1 did
not bind to this Sp1 site in the EPO promoter, confirm-
ing the specificity of the assay (Figure 7C).
Considering that the smallest fragment (-284/+59)
maintains the majority of the promoter activity respect to
the whole construct (Figure 5B), the nearest Sp1 sites
upstream of the TSS (+ 1), appear to be critical for the
ACVRL1 basal transcription. Interestingly, the -89/-56
fragment encompasses two adjacent Sp1 consensus ele-
ments, flanking a putative KLF6 binding site (Figure 7E).
This fragment was selected as a probe for EMSA studies.
A mobility shift appeared when nuclear extracts from
HeLa cells (Sp1 rich) were incubated with the labelled
probe and this binding was effectively competed with
100-fold excess of cold probe (Figure 7F). A supershift
was observed in the presence of an antibody specific for
Sp1 whereas anti-Sp3 or anti-NFB antibodies did not
affect the mobility shift, demonstrating the specificity for
Sp1. The slight decrease of the retarded band in the pre-
sence of anti-Sp3 may be explained by the fact that Sp1
and Sp3 often bind to the same sites. Furthermore, single
mutations of either Sp1 sites yielded retarded bands of a
weaker intensity, suggesting that both sites are binding
Sp1 independently. As negative controls, two Sp1 unre-
lated sequences, -823/-795 (containing consensus binding
sites for other transcription factors, none of them homo-
logous to Sp1 motifs) and AATT (double stranded poly
dA-poly dT) were unable to compete with the probe,
although with the AATT probe a slight non-specific
reduction of the signal was observed.
The methylation status modulates ALK1 expression in
endothelial cells
ACVRL1 promoter showed several GC-rich regions in
the in silico analysis of the -1,035/+210 bp fragment.
Using CpGPlot software, two CpG islands were identi-
fied, based on their parameters: 1) CG percentage >
50%; and 2) a ratio of observed-to-expected > 0.6. These
two islands comprise the regions between -408/-239 and
-177/+28 (Figure 8A). Because these GC-rich regions
are potential targets for Sp1 binding and methylation of
cytosines in CpG islands is one of the main epigenetic
modifications that regulate gene expression, we analyzed
whether ALK1 expression could be influenced by pro-
moter methylation. Indeed, as observed by real time
PCR, when endothelial HMEC-1 and HUVEC cells were
subjected to a treatment with the demethylating agent
5′-aza-2’-deoxycytidine (5-aza-dC), their ALK1 levels
were upregulated up to ~4,000-fold (Figure 8B). Inter-
estingly, HEK293T, a cell line that does not express
ALK1 under normal conditions (Figure 8C), underwent
~6,000-fold activation of ALK1 expression after treat-
ment with 5-aza-dC (Figure 8B). Likewise, Id1, which is
as p e c i f i ct a r g e tg e n eo ft h eA L K 1 / T G F - b1 signaling
cascade activation, became upregulated in parallel to the
increased levels of ALK1 in the three cell types (Figure
8B, C). Moreover, the activity of the reporter p(BRE)2-
luc, specific of the ALK1 signalling pathway, was
strongly enhanced upon treatment with 5-aza-dC. Con-
versely, the effect of in vitro hypermethylation was
assessed. ACVRL1 promoter constructs were methylated
in vitro with the CpG methyltransferase M.SssIa n dt h e
methylation status was checked by comparative diges-
tion of both mock and methylated ACVRL1 promoter
construct with HpaII (data not shown). Then, HEK293T
cells were transfected with mock-methylated or hyper-
methylated promoter constructs. As shown in Figure 9A
the transcriptional activity of all the ACVRL1 constructs
was completely abolished upon methylation. By contrast,
the activity of the prolactin promoter region driven by a
TATA box was almost unaffected (~80% versus
untreated), whereas the activity of Id1 promoter con-
struct was reduced at a much lower degree than the
ACVRL1 construct (11% versus 2% of pALK1 in
HEK293T; 29% versus 9% of pALK1 in HMEC-1) (Fig-
ure 9B). To assess whether the methylation status of the
Sp1 motifs affected the Sp1 binding, the -89/-56 radiola-
belled probe was competed with cold unmethylated and
methylated probes. As shown in Figure 9C, the
unmethylated probe clearly inhibited the Sp1 band,
whereas the methylated probe was unable to compete.
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Page 11 of 22Figure 7 Sp1 interacts with ACVRL1 promoter in HUVECs. (A) Scheme showing the primers used for Chromatin immunoprecipitation (ChIP).
The whole sequence of ACVRL1 promoter is mapped along four regions of approximately 200-250 bp. (B) Sp1 ChIP on ACVRL1 promoter in
HUVECs. The chromatin was digested obtaining a 150-300 bp fragments-enrichment. Anti-Histone 3 and a pool of rabbit-IgGs were used as
positive and negative controls. Input DNA was loaded before (Inp) and after (PInp) a preclearing process. (C) As a negative control of a gene
promoter that does not ChIP with Sp1, a fragment of erythropoietin (EPO) promoter was used [36]. (D) Sp1 binding to the different pALK1
regions from the ChIP experiment in B was measured by densitometry of the individual bands and values of the (Sp1-IgG)/PInput ratios were
represented. (E) Scheme of the ACVRL1 promoter fragment used as probe for EMSA assays and competitor mutant probes generated. (F)
Electrophoretic Mobility Shift Assays (EMSA) shows the binding of Sp1 to the -89/-56 bp region of ACVRL1 promoter. Two Sp1 sites and one
KLF6 site are framed in this region. EMSAs were performed with
32P-labelled WT probe. Cold probes were: WT; Mut A, mutated at the -84/-78
site; Mut B, mutated at the -67/-62 site; and two irrelevant sequences, the -823/-795 region of ACVRL1 promoter (-823) and AATT. A positive
control of Sp1 was included in lane 8 using a probe from ENG promoter as described in Methods. The retarded Sp1 band is indicated by the
arrow. The asterisks indicate the supershifted band obtained by addition of the anti-Sp1 antibody. The insert on the right, includes an over-
exposition of the supershift corresponding to lanes 14 and 15. As negative controls, anti-Sp3 and anti-NFB antibodies were included.
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Page 12 of 22Figure 8 Two CpG islands are present in the ACVRL1 promoter and treatment with the demethylating agent 5′-aza-2’-deoxycytidine
increases ALK1 expression in endothelial cells. (A) Schematic representation of the ACVRL1 promoter comprising the region -1,035 to + 210
bp. CG sites are depicted by black bars. Two CpG islands near the transcriptional start site were detected using CpGplot software tool. CG
content is shown as percentage the total number of G+C (top), and by the methylation-susceptible CG pairs, represented by the observed-
versus-expected index (bottom). (B, C) ALK1 and Id1 transcript levels from endothelial (HUVEC, HMEC-1) versus non endothelial (HEK293T) cells
prior and after treatment with the demethylating agent 5-aza-dC. Id1 mRNA levels were measured as a target gene of ALK1 signalling. (B) Cells
were treated with 1 μMo r5μM 5-aza-dC for one week. Treatment with 5 μM was cytotoxic in HUVEC. RNA was extracted and mRNA levels
were measured by real time RT-PCR. Results are shown as the fold change respect to basal expression (2
-ΔΔCt). (C) Basal ALK1 and Id1 levels
show the differences between ALK1 expression in endothelial cells HMEC-1 and HUVEC versus the HEK293T cells. (D) Effect of the demethylating
agent 5-aza-dC on the ALK1 pathway specific reporter, p(BRE) 2-luc, in HMEC-1 cells. Results are shown as fold change of expression levels or
luciferase activity (***p < 0.005).
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Page 13 of 22Figure 9 Effect of in vitro methylation on the ACVRL1 promoter activity. (A, B) Different reporter constructs were subjected to treatment
with M.SssI in the presence or absence of the substrate S-adenosyl-methyonine. Both mock-methylated and methylated constructs were
transfected in HEK293T and HMEC-1 cells and the luciferase activity was measured. (***p < 0.005; ns = not significant). (A) Analysis of the
different pALK1 reporter constructs. Results are shown as fold changes of luciferase activity (B) Analysis of a TATAbox minimal promoter (see
Methods), the Id1 promoter construct and the -1035/+210 pALK1 reporter construct. Activities of untreated samples were given the arbitrary
value of 100% and the activity of treated samples is indicated as percentage. (C) Electrophoretic mobility shift assay (EMSA) of the radiolabelled
-89/-56 probe containing two Sp1 functional sites. Competition was carried out using the unmethylated (U) or the in vitro methylated (M) probe,
as indicated.
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promoter strongly modulates ALK1 expression.
Discussion
The characterization of the 5′-proximal ACVRL1 pro-
moter fragment has allowed us to identify two new tran-
scripts, upstream of the previously published TSS. Those
transcripts include an upstream elusive exon, meaning
that ACVRL1 m a yh a v es e v e r a lT S S s .T h u s ,ACVRL1,
rather than showing a unique transcription start site,
contains different regions with a variable probability of
transcription initiation, a characteristic of TATA-less
genes. Interestingly, this is a common feature shared
between ACVRL1 and ENG. It is tempting to speculate
that the existence of different points of transcription
initiation may allow a more flexible regulation depend-
ing on the tissue, or the developmental stage of the cell.
In certain tissues like placenta, two main types of tran-
scripts have been reported [21,22]. In HUVECs we have
found two new transcripts that do not affect the open
reading frame of the encoded protein. In the new tran-
scripts, the first transcribed exon is not translated, and
therefore no changes in the predicted protein sequence
are observed. This observation emphasizes the impor-
tance of postranscriptional as well as transcriptional reg-
ulation mechanisms in the case of ACVRL1.T h e
existence of different transcribed untranslated regions
suggests regulation of ALK1 expression that involves the
transcriptional rate, mRNA stability or interaction with
other RNAs or RNA binding proteins. This feature is
compatible with the high degree of conservation found
among primates. Also, all the ACVRL1 transcripts
described in human, orangutan, rhesus monkey and
chimpanzee, seem to begin with an untranslated first
exon. Thus, ACVRL1 may have important motifs for
transcriptional regulation in the first exon. These motifs
are included in the promoter fragment that has been
subjected to study in this work.
Analysis of the basal promoter activity using lucifer-
ase-reporter experiments in a series of 5′-deleted mutant
constructs revealed the existence of positive and nega-
tive regulatory elements. Interestingly, the shortest con-
struct (-284/+59) displays a similar activity to that of the
whole fragment (-1,035/+210). This finding suggests the
existence of critical transcription factors binding to this
area in order to enhance the transcriptional activity of
the TATA-less ACVRL1 promoter. In agreement with
this view, a high degree of conservation around the + 1
TSS among different species was found. The analysis
also suggests the presence of a putative “repressor” seg-
ment between -422 and -284 positions, which inhibits
ACVRL1 transcription. Interestingly, a similar region is
found in the ENG promoter further upstream [30],
something that deserves further investigation.
The in silico study of the ACVRL1 promoter sequence
showed several important putative consensus elements,
also found in ENG promoter [30,32] that could be criti-
cal for the coordinated transcriptional regulation of
these genes. This finding suggests that genes involved in
the same functional pathway are controlled in a similar
manner. Thus, ACVRL1 may be regulated by some of
the transcription factors also controlling ENG expres-
sion. In this sense, because ENG is regulated by HIF-1,
Smad, KLF6, Ets, or Sp1 [31-33,37], it will be of interest
to assess their functional implications in ACVRL1.O f
note, three sequences matching HIF-1a motifs were
found at positions -808/-792, -286/-274 and -236/-219
bp. The possibility that ACVRL1 could respond to HIF-
1a is supported because hypoxia promotes angiogenesis,
a process that is regulated by ALK1. In addition, multi-
ple KLF consensus elements are dispersed along the
ACVRL1 promoter region. Interestingly, this is another
feature owing to the TGF-b receptor complex genes, in
which the transcription is stimulated by KLF6 as an
e a r l yi n j u r yr e s p o n s e[ 1 8 , 3 2 ] .O nt h eo t h e rh a n d ,t h e
presence of multiple Ets sites, suggests regulation by
MAPKs (Mitogen Activated Protein Kinases) [38]. In
this sense, in the functionally related gene, ENG,a nE t s
functional site was described in the proximal promoter
[ 3 0 ] .W ea l s on o t et h a tt h ep r e s e n c eo fA P 1a n dN F B
sites suggests that ACVRL1 could be a target for the
inflammatory response. In contrast to the ENG proximal
promoter that contains abundant SBE motifs, only a sin-
gle putative SBE was found at -270 bp position of the
ACVRL1 promoter. Also, at variance with ENG,t h e
ACVRL1 promoter does not contain any TGF-b-respon-
sive element (SBE) in the neighbourhood of Sp1 sites.
Moreover, the TGF-b receptor type I (ALK5) gene
(TGFBRI), contains a SBE within the proximal promoter
and both ENG and TGFBRI mRNA expression is upre-
gulated by TGF-b [30,39]. Thus, the proximal region of
ENG is regulated by TGF-b through Smads, and a direct
cooperation Smad/Sp1 giving rise to an important
increase in transcription [31]. Consistent with the lack
of proximal responsive TGF-b elements within the
ACVRL1 promoter, we found that its promoter activity
was not regulated by TGF-b1o rB M P 9 .T h i sd o e sn o t
exclude the possibility of a transcriptional regulation by
TGF-b from SBEs placed further upstream, or by an
indirect postranscriptional control through modifications
of the receptor, which allow or prevent ALK1 to activate
signalling through Smads. Addressing the functionality
of all these transcription factors in the ACVRL1 promo-
ter deserves an independent investigation. The present
work has focused on the functional role of Sp1 on
ACVRL1 basal transcription.
The most striking feature revealed by the in silico ana-
lysis of ACVRL1 is the presence of multiple Sp1 sites
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described as a general transcription factor involved in
transcriptional basal mechanisms of gene promoters that
lack TATA and CAAT core boxes. This is a shared
characteristic among different housekeeping genes [40].
Interestingly, this is also the case of several TGF-b
receptors such as ENG and TGFBR1, whose transcrip-
tion is driven by Sp1 [30,31]. Further support for the
i n v o l v e m e n to fS p 1w a so b t a i n e df r o mt h eh i g h l yc o n -
served alignment of the Sp1 consensus sites along the
ACVRL1 promoter among several species that suggests
a conserved biological relevance of Sp1 in the transcrip-
tion of ACVRL1.
We have demonstrated here that Sp1 is a key factor
necessary for the basal activation of ACVRL1 transcrip-
tion. This effect has been observed both by Sp1 overex-
pression in cells lacking endogenous Sp1, and by
interfering endogenous Sp1 with siRNA in mammalian
cells. The large number of Sp1 consensus sites found in
the ACVRL1 promoter, and the finding that small
amounts of Sp1 can saturate its transcription, points out
to a critical dependence on Sp1, and a fine tuning of
ACVRL1 transcription by Sp1. Furthermore, a ChIP ana-
lysis in HUVECs after chromatin crosslinking revealed
that Sp1 binds in vivo to the different consensus motifs
along the whole proximal ACVRL1 promoter sequence
studied (-1,032/+40). Thus, in endothelial primary cells
growing in a rich medium, Sp1 may be binding to most
o ft h es p e c i f i cm o t i f sw i t h i nt h eACVRL1 promoter
region. It can be speculated that the Sp1 binding to the
starting transcriptional machinery complex is needed to
ensure a transcription driven by Sp1 using different TSSs.
Because the closest region to the + 1 TSS is framed by
the construction -284/+59 pALK1 and its transcriptional
levels are similar to those of the -1,035/+210 pALK1
vector, probably the functional involvement of Sp1 for
ACVRL1 transcription initiation is critical in this region.
When searching the Sp1 consensus sites within this
region, an interesting double site in the -89/-56 region
was found. This Sp1 rich fragment contains two putative
Sp1 consensus sites (-84/-78 and -67/-62) and, as shown
in EMSA experiments, both sites are functional in bind-
ing to Sp1.
One key factor that modulates the Sp1 transcription
dependency is the degree of methylation of the CpG
islands contained within the Sp1 consensus elements.
This is consistent with the observation that DNA methy-
lation may interfere with the binding of Sp1 to DNA
[41]. In fact, we found that methylation of the -89/-56
Sp1 probe of ACVRL1 rendered this consensus motif
inactive for Sp1 binding. It is well established that DNA
methylation of CpG islands is an important mechanism
for transcriptional regulation of multiple genes in mam-
mals [42]. However, most of these findings are related to
proto-oncogenes, meaning that the hypermethylation is a
protective mechanism for controlling the transcriptional
switch to oncogenes. On the other hand, hypomethyla-
tion of tumor suppressor genes is a control mechanism
for assuring its transcriptional rate. However, there are
not many reports of genes non-related to cancer that
could be controlled by their methylation state. For exam-
ple, demethylation of certain promoters is involved in the
return of somatic cells to previous undifferentiated stages
of their cell lineage, and in the reprogramming to a new
differentiating pathway in response to certain stimuli
[43]. In some genes, cytosine methylation of Sp1 sites has
been reported as a marker of organ-specific expression
and as a specific regulator of the expression [44]. That
could be the case of ACVRL1, in which demethylation of
DNA in endothelial cells leads to a marked increase of
ACVRL1 transcription, potentially because demethylation
of CpG islands within the Sp1 sites is involved in
ACVRL1 basal transcription.
ALK1 expression has been reported in several cell
types, but its major roles are related to its predominant
expression in endothelium. The ALK1 specific presence
at the endothelial cell surface is tightly involved in the
regulation of the TGF-b signalling pathway in balance
with other type I TGF-b receptors [35]. The endothelial
specific expression may be explained by the presence
within the proximal promoter region of ACVRL1 of
c o n s e n s u sm o t i f sf o rt r a n scription factors (Ets, NFB,
Sp1 and KLFs) also shared by other endothelial specific
genes such as ENG, PECAM1 (Platelet Endothelial Cell
Adhesion Molecule 1), VEGFR2 (Vascular Endothelial
Growth Factor Receptor 2), CDH5 (Cadherin 5), eNOS/
NOS-3,o rTIE2 (Tyrosine kinase with Immunoglobulin-
like and EGF-like domains 2) [30,31,45-49]. In addition,
the involvement of distal regulatory regions in the
human ACVRL1, such as the one described in mouse
that confers arterial endothelium-specificity, can not be
excluded [50]. Whether the degree of ACVRL1 methyla-
tion correlates with the endothelial specific expression
of ALK1, remains to be explored.
Conclusions
Novel ACVRL1 transcripts have been identified, the
ACVRL1 promoter has been characterized and its regu-
lation by Sp1 has been demonstrated. Furthermore, a
close dependence between ACVRL1 expression and the
CG methylation degree was found. Future experiments
to identify other trans-acting or trans-repressing factors
in ACVRL1 regulation remain to be addressed.
Methods
5′Rapid Amplification of cDNA Ends (5′RACE)
RNA from human umbilical vein endothelial cells
(HUVEC) was extracted and purified with RNeasy
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Page 16 of 22(Qiagen, Hilden, Germany) following the manufacturer’s
protocol. 5′ RNA-Ligase-Mediated rapid amplification of
cDNA ends (RLM-RACE) was carried out according to
the manufacturer’s instructions (Ambion Inc., Austin,
TX, USA). Prior to the reverse transcription-polymerase
chain reaction (RT-PCR), total RNA was treated with
calf intestinal phosphatase (CIP) to remove the 5′phos-
phate from all RNA species except intact mRNA bearing
the the 5′ CAP structure. Then, tobacco acid pyropho-
sphatase (TAP) was used to remove the cap structure
from mRNA leaving a 5′-phosphate exposed and avail-
able for the subsequent ligation. The use of a CIP/TAP-
pre-treatment increases 5′RACE selectivity by avoiding
the presence of false PCR amplification products, by
selecting the complete mRNAs from the total RNA
population. Next, a synthetic RNA oligonucleotide was
added and ligated to the CIP/TAP treated RNA and the
chimeric RNA was reverse transcribed using random
primers. RT-PCR was performed with the avian-myelo-
blastosis virus (AMV) reverse transcriptase (RT) kit
(Roche Diagnostics, Mannheim, Germany). The result-
ing cDNA was used as a template for two nested PCR.
PCR was performed using different forward oligonucleo-
tides complementary to the 5′RACE adapter and two
reverse ACVRL1-specific primers, outer and inner,
respectively. The sequences of the primers are indicated
in Table 2. PCR was performed using an annealing tem-
perature of 58°C, and with HotMaster Taq polymerase
(Eppendorf, Westbury, NY, USA).
Real time PCR
For quantitative analysis, total RNA was isolated from
cells using the RNeasy kit (Qiagen) and was reverse-
transcribed using AMV reverse transcriptase (Roche
Diagnostics). The resultant cDNA was used as a tem-
plate for real time PCR performed with the primers
s h o w ni nT a b l e2u s i n gt h ei QS y B R - G r e e nS u p e r m i x
(BioRad, Hercules, CA, USA). Amplicons were detected
using an iQ5 real time detection system (BioRad). Tran-
script levels were normalized to 18S levels. Triplicates of
each experiment were performed.
Cloning of the ACVRL1 promoter fragment
Ag e n o m i cACVRL1 fragment corresponding to the 5′-
proximal region upstream the (+ 1) TSS was cloned into
SacI/XhoI sites of the reporter vector pGL2-luc contain-
ing the promoterless firefly luciferase gene (Promega,
Madison, WI, USA). This construct comprises 1,244 bp
and extends from the position 50,586,434 to 50,587,679
of the contig (GenBank: NC_000012.10. Reference
Assembly). The construct was checked by sequencing
with pGL primers 1 (Forward) and 2 (Reverse) (Pro-
mega) and the resulting sequence was identical to that
of the GenBank.
Alignment among different species and in silico analysis
of the ACVRL1 promoter
The human ACVRL1 promoter sequence was compared
with the orthologous promoters in a set of animal spe-
cies. The sequences to be compared were chosen by
identifying the theoretical + 1 TSS and then aligning the
human -1,035/+210 bp region. The accession numbers
of the different contigs and the sequences used are:
Mus musculus [GenBank:NT_039621] 62,243,937 -
62,245,182, plus strand; Rattus norvegicus [GenBank:
NW_047784] 6,594,766 - 6,596,011, plus strand; Bos
taurus [GenBank:NW_001495018] 123,378 - 122,133,
minus strand; Canis familiaris [GenBank:NW_76284]
3,087,613-3,086,368, minus strand; Pan troglodytes [Gen-
Bank:NC_006479] 2,296,228 - 2,294,983, minus strand;
Pongo pygmaeus [EMBL:413.52] 51,613,841 - 51,615,086,
plus strand; and Macaca mulatta [GenBank:
NW_001096621] 1,104,215 - 1,105,460, plus strand. For
the in silico analysis of the putative response elements,
we used the Genomatix MatInspector software tool:
http://www.genomatix.de/products/MatInspector. The
multiple sequence alignment was performed with the
ClustalW2 software http://www.ebi.ac.uk/Tools/clus-
talw2, which generates a similarity score (values from 1
to 100) and provides a consensus proposal. Weblogo
tool http://weblogo.berkeley.edu/logo.cgi was very useful
to make the graphic representation of these consensus
regions.
Generation of 5′deleted fragments of the human ACVRL1
promoter cloned into pGL2
Four different constructs with serial deletions of the
ACVRL1 promoter were generated by PCR amplifica-
tion, using primers designed to generate fragments with
differences of ~150 bp between each other. All the
sequences of the cloning primers are given in Table 2.
Forward primers were at positions: -898/-880, -587/-
569, -422/-404 and -281/-263. In all cases, the reverse
primer was at positions: + 42/+59. The amplified frag-
ments were: pALK1 -898/+59 (957 bp); pALK1 -587/
+59 (646 bp); pALK1 -422/+59 (481 bp) and pALK1
-284/+59 (343 bp). The resulting products were purified
a n dc l o n e di n t op C R 2 . 1 - T O P O - T Av e c t o r( I n v i t r o g e n ,
Carlsbad, CA, USA). Then, they were digested using
SacIa n dXhoI flanking restriction sites, inserted in
pGL2-luc and checked by sequencing with commercial
pGL primers 1 and 2 as described above.
Cell culture
Drosophila Schneider S2 cells were grown in Droso-
phila-enriched Schneider’s (DES) insect medium (Sigma
Aldrich, St Louis, MO, USA) supplemented with 10%
fetal bovine serum (FBS), 0.1 μg/μl gentamicin and 2
mM L-glutamine. The human microvasculature
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Page 17 of 22Table 2 Primers and probes used
5′RACE RNA-adapter GCUGAUGGCGAUGAAUGAACACUGCGUUUGCUGGCUUUGAUGAAA
5′RACE PRIMERS
5′RACE-adapter outer primer Fwd 5′-GCTGATGGCGATGAATGAACACTG-3′
ACVRL1 specific outer primer Rev 5′-GGGAGAGTCCAGTCTCATCCTGAA-3′
5′RACE-adapter inner primer Fwd 5′-CGCGGATCCGAACACTGCGTTTGCTGGCTTTGATG-3′
ACVRL1 specific inner primer Rev 5′-GCAGTAGTGGTTGACGAACTCGGT-3′
pALK1 CLONING PRIMERS
Cloning primer (-898/-880) Fwd 5′-GAAGCCATTCTGCTTCCC-3′
Cloning primer (-587/-569) Fwd 5′-ACAAATGGGGGACGAAGG-3′
Cloning primer (-422/-404) Fwd 5′-AAGGATAGGTAGTGTCCC-3′
Cloning primer (-284/-263) Fwd 5′-ACGTTGCCTACAGTCTCG-3′
Cloning primer (+42/+59) Rev 5′-ATTCCAGCGTCTTCCTGC-3′
PCR PRIMERS
hALK1 primer Fwd 5′-ATCTGAGCAGGGCGACAGC-3′
hALK1 primer Rev 5′-ACTCCCTGTGGTGCAGTCA-3′
h18S primer Fwd 5′-CTCAACACGGGAAACCTCAC-3′
h18S primer Rev 5′-CGCTCCACCAACTAAGAACG-3′
hSp1 primer Fwd 5′-TGCAGCAGAATTGAGTCACC-3′
hSp1 primer Rev 5′-TTGGTACTGCTGCCACTCTG-3′
hGAPDH primer Fwd 5′-AGCCACATCGCTCAGACAC-3′
hGAPDH primer Rev 5′-GCCCAATACGACCAAATCC-3′
hId1 primer Fwd 5′-GCTGCTCTACGACATGAACG-3′
hId1 primer Rev 5′-CTCCAACTGAAGGTCCCTGA-3′
ChIP PRIMERS
pALK1 First region primer (-1032/-1012) Fwd 5′-CCAGAAGGCTAGGACTAAGA-3′
pALK1 First region primer (-844/-864) Rev 5′-CTCCCTGGAACTCTGCTGAC-3′
pALK1 Second region primer (-864/-844) Fwd 5′-GTCAGCAGAGTTCCAGGGAG-3′
pALK1 Second region primer (-662/-682) Rev 5′-TTAGCCCTGAGGATGGTTTG-3′
pALK1 Third region primer (-510/-490) Fwd 5′-AAAACGCATCTGGATTTTGC-3′
pALK1 Third region primer (-260/-280) Rev 5′-GAGCCGAGACTGTAGGCAAC-3′
pALK1 Fourth region primer (-200/-180) Fwd 5′-CCCACGGCCTGAGTCCAAGG-3′
pALK1 Fourth region primer (+20/+40) Rev 5′-GGCCCAGCTCCTCCACTCC-3′
pEPO primer Fwd (-66/-42) 5′-AGCCTCTCCCCCACCCCCAGCCCGGCG-3′
pEPO primer Rev (+31/+9) 5′-CAGCCCGCGAGTACTCACCGTG-3′
EMSA PROBES
Sp1 sites WT pALK1 (-89/-56) Fwd 5′-CTGAGGGGCTGGGAGCGGCGCGGGGGTGGGTCCC-3′
Sp1 sites WT pALK1 (-89/-56) Rev 5′-GGGACCCACCCCCGCGCCGCTCCCAGCCCCTCAG-3′
Sp1 site MutA -84/-78 pALK1 Fwd 5′-CTGAGTTTTTTGGAGCGGCGCGGGGGTGGGTCCC-3′
Sp1 site MutA -84/-78 pALK1 Rev 5′-GGGACCCACCCCCGCGCCGCTCCAAAAAACTCAG-3′
Sp1 site MutB -67/-62 pALK1 Fwd 5′-CTGAGGGGCTGGGAGCGGCGCGTTTTTTTGTCCC-3′
Sp1 site MutB -67/-62 pALK1 Rev 5′-GGGACAAAAAAACGCGCCGCTCCCAGCCCCTCAG-3′
pENG (-50 and -24 sites) Fwd 5′-GCAGGCGGCCTGGGCCCAGCCCCTTCTC-3′
pENG (-50 and -24 sites) Rev 5′-GAGAAGGGGCTGGGCCCAGGCCGCCTGC-3′
pALK1 (-823/-795) Fwd 5′-TAAAGGTCCATTTGCTGGGGTGGGGGCCC-3′
pALK1 (-823/-795) Rev 5′-GGGCCCCCACCCCAGCAAATGGACCTTTA-3′
AATT probe Fwd 5′-AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA-3′
AATT probe Rev 5′-TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT-3′
Note: Characters in bold/underlined in EMSA probes indicate mutated nucleotides.
Garrido-Martin et al. BMC Molecular Biology 2010, 11:51
http://www.biomedcentral.com/1471-2199/11/51
Page 18 of 22endothelial cell line HMEC-1 was grown on 0.2% gelatin
(Sigma Aldrich) pre-coated plates in MCDB-131 med-
ium (Gibco, Paisley, UK) supplemented with 10% FBS, 2
mM L-glutamine, 1 ng/mL Epidermal Growth Factor
(EGF) and 1 μg/ml hydrocortisone. Primary HUVEC
were grown in EBM2 medium supplemented with
EGM2 (Lonza, Walkersville, MD, USA) and containing
10% FBS. Human epithelial embryonic kidney HEK293T
cells were cultured in Dulbecco’sm o d i f i e dE a g l e ’s med-
ium (DMEM) with 10% FBS. All the media were supple-
mented with both 100 U/ml penicillin-streptomycin.
DNA transfections and luciferase assays
Transfections of HEK293T, HMEC-1 and Schneider S2
cells were performed using the Superfect Reagent (Qia-
gen) following the commercial instructions. When
required, transfected cells were treated for 3 hours
with 1 ng/ml of TGF-b1 (R&D Systems, Minneapolis,
MN, USA) or 16 hours with 0.5 ng/ml of BMP9 (R&D
Systems) in the presence of 2% FBS. The expression
vector pCIneo-Sp1 was used to transfect mammalian
cells, whereas pPac-Sp1 was used to transfect Droso-
phila Schneider S2. The corresponding empty vectors
were used as controls. Forty eight hours after transfec-
tion with the pGL2 reporter vectors, cells were har-
vested and the luciferase activities were determined in
a TD-20/20 luminometer (Promega). In all cases, the
pCMV-bGal vector was included in the transfections
and its transcriptional activity was measured as an
internal control. After normalization, the activity of the
reporter constructs was referred to the basal activity as
fold induction or as percentages with respect to
controls.
Sp1 knock down
The human Sp1 small interfering ribonucleic acid
(siRNA) was obtained from Santa Cruz Biotechnology
(sc-29487, Santa Cruz, CA, USA). HEK293T cells were
transfected with 5 pmoles of siRNA hSp1 or scrambled
siRNA, using lipofectamine 2000 (Invitrogen, Carlsbad,
CA, USA). Twenty four hours later, the pALK1 reporter
construct and the Renilla normalization plasmid were
transfected, using the Superfect Reagent (Qiagen). Luci-
ferase activity was measured 24 hours after DNA trans-
fection with the Dual Luciferase Assay System
(Promega). Values were normalized to Renilla activity
and values were referenced to the basal activity (100%)
in each case. Lysates from these cells at 48 hours post-
transfection were analyzed by semiquantitative RT-PCR
using the primers indicated in Table 2 and by western
blot using the rabbit polyclonal antibody anti-Sp1
(PEP2, SC-59, Santa Cruz Biotechnology) and monoclo-
nal mouse antibody anti-b-actin antibody AC15 (A1978,
Sigma Aldrich).
Chromatin immunoprecipitation (ChIP)
ChIP was performed with ChIP-IT Express kit (Active
motif, Rixensart, Belgium), following the manufacturer’s
instructions. Briefly, HUVEC were grown to confluence
and subsequently fixed with 1% formaldehyde. Cells
were scraped in the presence of PMSF (phenylmethyl-
sulphonyl fluoride) and lysed. Nuclei were separated
using a dounce homogenizer and digested with enzy-
matic shearing cocktail for 15 min. One aliquot of this
sheared chromatin was used as “input chromatin” and
the rest was incubated with protein G magnetic beads
and rabbit polyclonal antibody against human Sp1 PEP2
(SC-59, Santa Cruz Biotechnology) on a rolling shaker
for 4 hours at 4°C. The positive control was incubated
with rabbit polyclonal anti-human Histone 3 (ab8580,
Abcam, Cambridge, MA, USA) and the negative control
with serum anti-human IgG. Protein G magnetic beads
bound to the immune complexes were pelleted, washed
and bound proteins were eluted with the elution buffer
provided with the kit. Then, the crosslinking was
reversed and samples were incubated with proteinase K
during 1 h at 37°C. Primers used for PCR were selected
by mapping the whole promoter sequence, separated
into four regions. The first region encompasses from
-1,032 to -844 (188 bp); the second region from -864 to
-662 (202 bp); the third region from -510 to -260 (250
bp) and the fourth region from -200 to + 40 (240 bp).
Sequences of the four couples of primers are indicated
in Table 2. For negative and positive control PCR, pri-
mers from ChIP-IT control kit human (Cat # 53010,
Active motif) were used (data not shown). Measurement
of the Sp1 binding was carried out using the following
ratio of band intensities: (Sp1-IgG)/PInput.
Electrophoretic mobility shift assay (EMSA)
For the radiolabelled probe, the oligonucleotides were
designed in the region -89/-56 of the ACVRL1 promo-
ter, which includes two Sp1 consensus sites flanking a
Krüppel-like factor-6 (KLF6) site. Competition experi-
ments were carried out with five cold probes: i) -89/-56
wild type (WT); ii) -89/-56 with the site -84/-78
mutated; iii) -89/-56 with the site -67/-62 mutated; iv)
-823/-795, containing consensus binding sites for other
transcription factors, none of them homologous to Sp1
motifs; and v) AATT, an artificial competitor, double
stranded poly dA-poly dT sequence, unrelated to the
ACVRL1 promoter. The corresponding sequences are
shown in Table 2. Probes were prepared by annealing
complementary synthetic oligonucleotides followed by
end labelling with [g
32P]dATP and T4 polynucleotide
kinase. Nuclear extracts from HeLa cells were obtained
from Promega (Cat # E3521). Approximately 5 ng
(100,000 cpm) of the respective probe was incubated
with 10 μg of nuclear extract and 2 μg/reaction of poly
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Page 19 of 22(dI-dC) for 30 min on ice. For competition experiments,
a 100-fold excess of unlabeled double-stranded oligo-
nucleotide was added. For supershift assays, protein
extract and 1 μg of commercial antibody were preincu-
bated for 60 min on ice prior to the addition of the
remaining components of the binding reaction. Rabbit
polyclonal antibodies anti-Sp1 (PEP2, SC-59), anti-Sp3
(SC-644) and anti-NFB (Nuclear Factor kappa-light-
chain-enhancer of activated B cells) (H-119, SC-7178)
were purchased from Santa Cruz Biotechnology.
Positive control binding reactions were performed
with a probe designed for the ENG promoter (-50/-24
Sp1 sites), which strongly binds Sp1 [31]. Binding reac-
tions were separated by nondenaturing 6% polyacryla-
mide gel electrophoresis in Tris-Borate-EDTA buffer at
4°C. Gels were dried, and visualized by autoradiography.
EMSAs were repeated at least three times with similar
results.
Treatment of cells with the demethylating agent 5′-aza-
2’-deoxycytidine
CpG islands were detected using the software tool
CpGplot http://www.ebi.ac.uk/Tools/emboss/cpgplot/
index.html. HUVEC, HMEC-1, and HEK293T cells were
treated with 5′-aza-2’-deoxycytidine (5-aza-dC; Sigma
Aldrich) at a final concentrations of 1 μMo r5μMf o r
7 days and the medium was changed every second day,
according to Butta et al., [51]. Finally, cells were lysed,
total RNA was extracted with RNeasy kit (Qiagen) and
the ALK1/Id1 ratio was measured by real time PCR. Pri-
mers used are shown in Table 2.
For functional experiments, after a one week of treat-
ment with 5 μM 5-aza-dC, HMEC-1 cells were transfected
with the specific reporter of the ALK1 pathway p(BRE)2-
luc (BMP-responsive firefly luciferase reporter), which
contains a small sequence with two copies of the regions
(-1052/-1032)/(-1105/-1080) of the Id1 promoter [52].
In vitro methylation of promoters
Constructs -1,035/+210, -898/+59, -587/+59, -422/+59
and -284/+59 of ACVRL1 promoter and the reporter
plasmids of Id1 promoter (pGL2-pId1) and the rat mini-
mal prolactin promoter region -36 to + 37 surrounding
a TATA box, (pXP2-TATAbox) [53] were methylated
in vitro by the CpG methylase M.SssI( N e wE n g l a n d
Biolabs, Ipswich, MA, USA) in the absence or presence
of the substrate S-adenosylmethionine. The methylation
status was checked by digestion with the restriction
enzyme HpaII, which digests the target sequence CCGG
b u to n l yw h e ni ti su n m e t h y l a t e d( d a t an o ts h o w n ) .
Cells were transfected with 100 ng of the indicated
mock-methylated or methylated ACVRL1 promoter
reporter, 100 ng of pCIneo-Sp1 and with Renilla repor-
ter vector. Luciferase activity was measured after 48
hours and normalized to Renilla activity. For electro-
phoretic mobility shift assays, the cold probe (-89/-56)
of ACVRL1 promoter was subjected to in vitro methy-
lation with the CpG methylase M.SssI prior to competi-
tion with the radiolabelled probe.
Statistics
Data were subjected to statistical analysis and results are
shown as mean ±SD. Differences in mean values were
analysed using Student’s t-test. In the figures, the statis-
tically significant values are marked with asterisks
(*p < 0.05; **p < 0.01; ***p < 0.005; ns = not significant).
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